Or the chronic wound study comes back with positive results that allow for reimbursement by insurance.
That's another $600m market opened up right there (according to PNV's estimates, I'd argue that's an underestimate).
The study is due to be finished this month. I don't know how quickly things get approved for reimbursement in the states but that market may not be far off.
Ann: FY21 BTM Revenue Results, page-164
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.54 |
Change
-0.180(6.62%) |
Mkt cap ! $1.753B | |||
| Open | High | Low | Value | Volume |
| $2.62 | $2.65 | $2.53 | $4.356M | 1.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 29641 | $2.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.55 | 22158 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |